tru Independence’s Tvardi Therapeutics TVRD Stock Holding History

tru Independence’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-31	Closed	-$19	–	879
2020 Q2	$19	Buy	+31	New	+$17.1K	﹤0.01%	510

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

tru Independence's TVRD Position: Q3 2020 in Review

tru Independence sold out of Tvardi Therapeutics (TVRD) in Q3 2020, closing a stake of 31 shares — an estimated $19 sold.

tru Independence first reported a position in TVRD in Q2 2020 and held it in 1 quarter. The position peaked at $19 in Q2 2020. 160 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

tru Independence reported no remaining Tvardi Therapeutics position as of Q3 2020 after selling out during the quarter.
tru Independence sold 31 Tvardi Therapeutics shares in Q3 2020, an estimated $19.
tru Independence first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 1 quarter.
tru Independence's Tvardi Therapeutics position peaked at $19 in Q2 2020.
160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.